We aimed to assess the effect of a functional polymorphism of CYP3A5 on lumefantrine pharmacokinetics. Sixty-nine women diagnosed with malaria received standard doses of artemether-lumefantrine. Concentration-time data for lumefantrine and genotyping data were obtained for each participant. Pharmacokinetic-genotype associative relationships were assessed using linear regressions, Mann-Whitney U-test or Kruskal-Wallis statistics. Average age and weight (standard deviation) of the patients were 33 (6.8) years and 59.5 (11.6) kg, respectively. genotype associated with the log-transformed maximum concentration with the median (interquartile range) values of 8279 (6516-13,420) and 6331 (4093-8631) ng/ml (p = 0.032) among the carriers and noncarriers of , respectively. Besides, the c.152-1089T>C genotypes had an associative trend with the lumefantrine area under the curve (AUC) and clearance. *3 genetic variant is associated with a high maximum plasma concentration of lumefantrine. This warrants further investigations on the association between gene variants, lumefantrine pharmacokinetics and electrophysiological effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pgs-2020-0081 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Extended Treatment Duration of Artemether-Lumefantrine in Ugandan Children with HIV on Efavirenz-Based Antiretroviral Therapy: A Randomized Controlled Pharmacokinetic and Pharmacodynamic Trial.
J Clin Pharmacol
January 2025
Infectious Disease Research Collaboration, Kampala, Uganda.
Malaria and HIV co-infection are prevalent in sub-Saharan Africa causing significant drug interactions with co-treatment. We previously reported a 30%-70% reduction in exposure to the standard 3-day (6-dose) artemether-lumefantrine (AL) treatment for malaria when given with efavirenz-based HIV therapy, impacting malaria reinfection risk. We conducted a prospective, randomized study comparing the 3-day regimen to an extended 5-day (10-dose) regimen with pharmacokinetic sampling for artemether, dihydroartemisinin, lumefantrine, and desbutyl-lumefantrine (DBL) over 42 days.
View Article and Find Full Text PDFSynthesis of New Enantiopure Aminoalcohol Fluorenes as Promising Antimalarial Compounds.
ChemMedChem
December 2024
UFR de Pharmacie, Université de Picardie Jules Verne, Amiens, France.
Herein, we report the design, synthesis, and characterisation of a new library of enantiopure aminoalcohol fluorenes, as well as their in vitro evaluation for biological properties, including activity against two strains of P. falciparum (3D7 and W2) and cytotoxicity on the HepG2 cell line. All tested compounds exhibited good to excellent antimalarial potency with IC values ranging from 0.
View Article and Find Full Text PDFMulti-method coamorphous systems of lumefantrine with alpha ketoglutaric acid: Comprehensive characterization, biological evaluation and stability analysis.
Int J Pharm
January 2025
Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana 500037, India. Electronic address:
Article Synopsis
- Researchers developed coamorphous systems (CAM) using lumefantrine (LMF) and alpha-ketoglutaric acid (KGA) to improve LMF's solubility and bioavailability through three distinct methods: liquid-assisted grinding, solvent evaporation, and quench-cooling.
- Testing via PXRD, DSC, and other techniques confirmed the successful amorphization and intermolecular interactions in these CAMs, along with simulations showing diverse molecular environments.
- The new CAMs significantly enhanced solubility (up to 14.73x), dissolution rates (up to 2.63x), and pharmacokinetics in living organisms (up to 10.86x), while also demonstrating anti-cancer
Characterizing the pharmacological interaction of the antimalarial combination artefenomel-piperaquine in healthy volunteers with induced blood-stage Plasmodium falciparum to predict efficacy in patients with malaria.
BMC Med
November 2024
QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Background: The combination antimalarial artefenomel-piperaquine failed to achieve target efficacy in a phase 2b study in Africa and Vietnam. We retrospectively evaluated whether characterizing the pharmacological interaction of this antimalarial combination in a volunteer infection study (VIS) would have enabled prediction of the phase 2b study results.
Methods: Twenty-four healthy adults enrolled over three consecutive cohorts were inoculated with Plasmodium falciparum-infected erythrocytes on day 0.
Optimizing Lumefantrine Dosing for Young Children in High-Malaria-Burden Countries Using Pharmacokinetic-Pharmacodynamic Simulations.
Open Forum Infect Dis
November 2024
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, USA.
Background: Artemether-lumefantrine is the most widely used treatment for uncomplicated malaria and it is dosed based on weight bands according to World Health Organization (WHO) guidelines. However, children are vulnerable to underdosing. Inadequate dosing can lead to treatment failure and drug resistance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!